Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials

被引：12
作者：
Markman, Maurie [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Med Oncol, Houston, TX 77030 USA
来源：
GYNECOLOGIC ONCOLOGY | 2007年 / 106卷 / 02期
关键词：
PEGYLATED LIPOSOMAL DOXORUBICIN; GYNECOLOGIC-ONCOLOGY-GROUP; INTRAPERITONEAL CISPLATIN; INTERGROUP TRIAL; STAGE-III; PACLITAXEL; RECURRENT; PLATINUM; WOMEN; CYCLOPHOSPHAMIDE;
D O I：
10.1016/j.ygyno.2007.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：279 / 281
页数：3
相关论文
共 11 条
[1]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[2]   Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer [J].
Gordon, AN ;
Tonda, M ;
Sun, S ;
Rackoff, W .
GYNECOLOGIC ONCOLOGY, 2004, 95 (01) :1-8
[3]   Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].
Gordon, AN ;
Fleagle, JT ;
Guthrie, D ;
Parkin, DE ;
Gore, ME ;
Lacave, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322
[4]   Viewing ovarian cancer as a "chronic disease": What exactly does this mean? [J].
Markman, M .
GYNECOLOGIC ONCOLOGY, 2006, 100 (02) :229-230
[5]   Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group [J].
Markman, M ;
Bundy, BN ;
Alberts, DS ;
Fowler, JM ;
Clark-Pearson, DL ;
Carson, LF ;
Wadler, S ;
Sickel, J .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :1001-1007
[6]   Why study third-, fourth-, fifth-, ... line chemotherapy of ovarian cancer? [J].
Markman, M .
GYNECOLOGIC ONCOLOGY, 2001, 83 (03) :449-450
[7]   Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial [J].
Markman, M ;
Liu, PY ;
Wilczynski, S ;
Monk, B ;
Copeland, LJ ;
Alvarez, RD ;
Jiang, C ;
Alberts, D .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2460-2465
[8]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[9]  
Parmar MKB, 2003, LANCET, V361, P2099
[10]   Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG [J].
Pfisterer, Jacobus ;
Plante, Marie ;
Vergote, Ignace ;
du Bois, Andreas ;
Hirte, Hal ;
Lacave, Angel J. ;
Wagner, Uwe ;
Staehle, Anne ;
Stuart, Gavin ;
Kimmig, Rainer ;
Olbricht, Sigrid ;
Le, Tien ;
Emerich, Janusz ;
Kuhn, Walther ;
Bentley, James ;
Jackisch, Christian ;
Lueck, Hans-Joachim ;
Rochon, Justine ;
Zimmermann, Annamaria Hayden ;
Eisenhauer, Elizabeth .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4699-4707
12